Trials / Active Not Recruiting
Active Not RecruitingNCT05526222
A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study of Jaktinib Hydrochloride Tablets in the Treatment of Adult Patients With Moderate and Severe Atopic Dermatitis
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 443 (actual)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter, randomized, double-blind, placebo-controlled phase III clinical study of jaktinib hydrochloride tablets in the treatment of adult patients with moderate and severe atopic dermatitis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Jaktinib Hydrochloride Tablet | Orally administered, twice a day |
Timeline
- Start date
- 2022-07-14
- Primary completion
- 2026-06-01
- Completion
- 2026-09-01
- First posted
- 2022-09-02
- Last updated
- 2026-01-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05526222. Inclusion in this directory is not an endorsement.